Document Detail

Comparative Effects of a Novel Angiotensin-Converting Enzyme Inhibitor versus Captopril on Plasma Angiotensins after Myocardial Infarction.
MedLine Citation:
PMID:  25171296     Owner:  NLM     Status:  Publisher    
The compound 4-tert-butyl-2,6-bis(thiomorpholin-4-ylmethyl)phenol (TBTIF) has molecular characteristics similar to angiotensin-converting enzyme (ACE) inhibitors of the sulfhydryl subclass. To assess its value as a new therapeutic agent, we performed a comparative analysis of the effect of TBTIF versus captopril on the circulating levels of angiotensin (Ang) peptides and bradykinin as well as ACE and ACE2 expression after myocardial infarction. Male Wistar rats were divided into four groups: (1) sham-operated rats; (2) rats subjected to 48 h of coronary artery ligation; (3) rats administered captopril (1 mg/kg, i.m.), and (4) a similar group of rats given TBTIF (1 mg/kg, i.m.). Both drugs were administered 30 min before coronary artery ligation and again 24 h later. Acute myocardial infarction lowered both systolic and left ventricular systolic blood pressures compared to the sham group and increased plasma levels of Ang I, Ang II, Ang(1-7) and Ang(1-12). Administration of either captopril or TBTIF reversed the increases in plasma angiotensins. Interestingly, the levels of plasma Ang(1-7) achieved by administration of TBTIF reached values higher than those recorded with captopril. Both agents reversed the decreases in plasma concentrations of bradykinin; in addition, TBTIF upregulated ACE expression, while both agents suppressed the ACE2 upregulation induced by myocardial infarction. These results demonstrate a beneficial effect of the novel compound TBTIF in suppressing the acute surge in the circulating renin-angiotensin system activity induced by myocardial infarction. The greater effects of this compound in augmenting plasma Ang(1-7) concentrations may be highly significant as drugs which augment the concentration of this heptapeptide will exert cardioprotective actions in part by suppressing the hypertrophic and profibrotic actions of Ang II. © 2014 S. Karger AG, Basel.
Jazmín Flores-Monroy; Carlos M Ferrario; Ignacio Valencia-Hernández; Maria Elena Hernández-Campos; Luisa Martínez-Aguilar
Related Documents :
25475946 - Myocardial preconditioning reduces kidney injury and apoptosis induced by myocardial is...
9316546 - Rest heart rate and life expectancy.
25389106 - Electrophysiological and antiarrhythmic properties of potassium canrenoate during myoca...
10455076 - Different microcirculatory and interstitial matrix patterns in idiopathic dilated cardi...
15326506 - Management of patients admitted with an acute coronary syndrome in new zealand: results...
25097196 - In-hospital switching between clopidogrel and prasugrel among patients with acute myoca...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-8-28
Journal Detail:
Title:  Pharmacology     Volume:  94     ISSN:  1423-0313     ISO Abbreviation:  Pharmacology     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-8-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0152016     Medline TA:  Pharmacology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  21-28     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Recent Advances on Hepatitis C Virus in Dialysis Population.
Next Document:  Au Photosensitized TiO2 Ultrathin Nanosheets with {001} Exposed Facets.